Researchers at the Federal University of Rio de Janeiro in Brazil, are planning to launch human trials of AIDS vaccines on 40 volunteers next month. The Brazilian team expects to have preliminary results by year-end for two vaccines, Aventis' Alvac and VaxGen's AIDSvax. A component of a vaccine development program coordinated by the U.S. National Institutes of Health and the HIV Network for Prevention Trials, the Brazilian results will help determine whether the trials should continue to Phase III. The trials will involve HIV-negative volunteers between the ages of 18 and 60 who are not injection drug users and have only had one sexual partner within the past six months.

Other CDC News for March 15, 2001

Effectiveness of the Direct Observation Component of DOTS for Tuberculosis: a Randomized Controlled Trial in Pakistan Maker Yielding Patent in Africa for AIDS Drug Antiviral Cocktails Cut Cost of Treating Patients With HIV South Africa Resists Call for AIDS Emergency	As AIDS Grows For Minorities, So Does Funding; Groups Assisting City's Blacks, Latinos Win Increased Support The Danger of Living "Down Low"; Black Men Who Hide Their Bisexuality Can Put Women at Risk A New AIDS Strategy Brazil to Launch AIDS Vaccine Human Trials in April
Mogae Warns Botswana Faces Extinction From AIDS